News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trevena, Inc. Completes Phase 2a Study of TRV027 in Patients With Advanced Heart Failure


10/8/2012 9:53:11 AM

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it has successfully completed a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced heart failure with reduced ejection fraction. TRV027 was generally well-tolerated in this study and produced beneficial hemodynamic effects in line with those observed in previously published pre-clinical studies. Trevena is developing TRV027 for the intravenous hospital treatment of acute decompensated heart failure (ADHF), and these data support the advancement of TRV027 into a future study to evaluate its clinical efficacy in patients with ADHF.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES